Alnylam Pharmaceuticals 주식 (NASDAQ: ALNY)

에 대한 최신 뉴스 Alnylam Pharmaceuticals (NASDAQ:ALNY) 주식

ALNYLAM PHARMACEUTICALS INC

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

The Robinhood Trade

Equities

Large Cap

News

Movers

Trading Ideas

ALNY

DUOL

ESLT

HOOD

MUFG

ROKU

SHOP

지난주에 가장 성과가 좋았던 대형주 10종목은 다음과 같다. 앨나일람, 로쿠, 로빈후드, 엘빗, 보잉, 앵글로골드, 쇼피파이, 사우스웨스트항공, 미쓰비시 파이낸셜, 듀오링고

로빈후드·로쿠·쇼피파이 등 지난주 급등한 대형주 (3월 17일~21일)

Coinbase Photo by rafapress on Shutterstock

COIN

MBLY

MRNA

RIVN

SMMT

STLA

FLSR

이들 11개 대형주들은 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?1. 휴마나(NYSE:HUM)가 별 등급의 2025년 실적 하락과 이것이 2026년 품질 보너스 지급에 어떤 영향을 미칠지에 대해 투자자들에게 업데이트한 후 주가는 24.89% 하락했다. 몇몇 분석가들은 주가 예측을 낮췄다.

코인베이스, 나이키 및 모더나는 지난주 최악의 성과를 보인 11개 대형주 중 일부 (9월 30일-10월 4일)

DoorDash

CHRW

COKE

CVNA

DASH

DXCM

EXAS

Laboratory Corporation Of America Holdings

PYPL

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 이그젝트 사이언스(NASDAQ:EXAS)가 예상보다 나은 2분기 재무 결과를 보고하고 트윈스트랜드 바이오사이언스(TwinStrand Biosciences)와 독점 라이센스 계약을 발표한 후 주가는 26.60% 상승했다. 몇몇 분석가들은 주식에 대한 가격 예측을 하향 조정했다.

도어대시와 이그젝트 사이언스는 지난주 최고 성과를 보여준 10개 대형주 중 일부 (7월 28일-8월 3일)

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals Inc

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>JP Morgan cut Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) price target from $240 to $230. JP Morgan analyst Samik Chatterjee maintained an Overweight rating. Apple shares closed at $201.56 on Wednesday. S<a href="https://www.benzinga.com/quote/AAPL/analyst-ratings">ee how other analysts view this stock</a>.</li>
<li>Jefferies cut the price target for The Clorox Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) from $167 to $145. Jefferies analyst Kaumil Gajrawala maintained a Buy rating. Clorox shares closed at $119.48 on Wednesday. <a href="https://www.benzinga.com/quote/CLX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity raised Worthington Enterprises, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOR#NYSE">WOR</a>) price target from $69 to $81. Canaccord Genuity analyst Brian McNamara maintained a Buy rating. Worthington shares closed at $61.35 on Wednesday. <a href="https://www.benzinga.com/quote/WOR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co boosted the price target for Kymera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) from $54 to $60. HC Wainwright &amp; Co. analyst Andrew Fein maintained a Buy rating. Kymera Therapeutics shares closed at $46.47 on Wednesday. <a href="https://www.benzinga.com/quote/KYMR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo cut the price target for The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) from $74 to $68. Wells Fargo analyst Alec Brondolo downgraded the stock from Overweight to Equal-Weight. Trade Desk shares closed at $69.80 on Wednesday. <a href="https://www.benzinga.com/quote/TTD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Citigroup raised Truist Financial Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFC#NYSE">TFC</a>) price target from $44 to $55. Citigroup analyst Keith Horowitz upgraded the stock from Neutral to Buy. Truist Financial shares settled at $41.40 on Wednesday. <a href="https://www.benzinga.com/quote/TFC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt raised Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) price target from $172 to $200. Rosenblatt analyst Kevin Cassidy maintained a Buy rating. Micron shares closed at $127.25 on Wednesday. <a href="https://www.benzinga.com/quote/MU/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham increased Alnylam Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) price target from $320 to $377. Needham analyst Joseph Stringer maintained a Buy rating. Alnylam Pharmaceuticals shares closed at $321.94 on Wednesday.  <a href="https://www.benzinga.com/quote/ALNY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Benchmark boosted the price target for Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) from $350 to $475. Benchmark analyst Mickey Legg maintained a Buy rating. Tesla shares settled at $327.55 on Wednesday. <a href="https://www.benzinga.com/quote/TSLA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird increased Concentrix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) price target from $62 to $72. Baird analyst David Koning maintained an Outperform rating. Concentrix shares closed at $54.17 on Wednesday. <a href="https://www.benzinga.com/quote/CNXC/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying TSLA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/TSLA/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="570" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26090911/image-410-1024x570.png" alt="" class="wp-image-963276" style="width:623px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26090911/image-410-1024x570.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26090911/image-410-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26090911/image-410-768x428.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26090911/image-410.png 1162w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46093486/top-2-utilities-stocks-that-may-fall-off-a-cliff-in-q2">Top 2 Utilities Stocks That May Fall Off A Cliff In Q2</a> </li>
</ul>
Photo via Shutterstock

Price Target

Markets

Analyst Ratings

AAPL

CNXC

KYMR

TSLA

Tesla To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Thursday

Needham analyst Joseph Stringer maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and raises the price target from $320 to $377.

Needham Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $377

BMO Capital analyst Kostas Biliouris maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Outperform and raises the price target from $300 to $360.

BMO Capital Maintains Outperform on Alnylam Pharmaceuticals, Raises Price Target to $360

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 20 years by 12.09% on an annualized basis producing an average annual return of 20.51%. Currently, Alnylam Pharmaceuticals has a market capitalization of $39.93 billion. 
Buying $1000 In ALNY: If an investor had bought $1000 of ALNY stock 20 years ago, it would be worth $40,864.67 today based on a price of $308.54 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750089617_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years

Ratings for Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) were provided by 18 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">11</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">9</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Alnylam Pharmaceuticals, presenting an average target of $339.39, a high estimate of $500.00, and a low estimate of $268.00. Surpassing the previous average price target of $324.29, the current average has increased by 4.66%.
<img src="https://www.benzinga.com/files/images/story/2025/1749736915_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Alnylam Pharmaceuticals by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$338.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Esther Rajavelu</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$349.00</td>
<td>$331.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$325.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Michael Ulz</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$268.00</td>
<td>$284.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$500.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$342.00</td>
<td>$338.00</td>
</tr>
<tr>
<td>Joshua Smith</td>
<td>Redburn Atlantic</td>
<td>Announces</td>
<td>Buy</td>
<td>$353.00</td>
<td>-</td>
</tr>
<tr>
<td>Paul Matteis</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$345.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$328.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>David Lebovitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$351.00</td>
<td>$338.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$390.00</td>
<td>$385.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$330.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$338.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$287.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$325.00</td>
<td>$302.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Alnylam Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Alnylam Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Alnylam Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Alnylam Pharmaceuticals's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ALNY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Alnylam Pharmaceuticals analyst ratings.</a>
<h2>Get to Know Alnylam Pharmaceuticals Better</h2>
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
<h3>Alnylam Pharmaceuticals's Economic Impact: An Analysis</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Alnylam Pharmaceuticals's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 20.2%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Alnylam Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of -9.67%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Alnylam Pharmaceuticals's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -62.98%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Alnylam Pharmaceuticals's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -1.36%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 11.28, caution is advised due to increased financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 18 Analyst Ratings Have To Say About Alnylam Pharmaceuticals

JP Morgan analyst Jessica Fye maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Overweight and raises the price target from $330 to $338.

JP Morgan Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $338

The approval broadens the indication for AMVUTTRA, which now becomes the first and only RNAi therapeutic approved by the EC for the treatment of the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy manifestations of hereditary transthyretin-mediated amyloidosis in adults.

Biotech

Health Care

General

The European Commission Approves  Alnylam Pharmaceuticals' Orphan RNAi Therapeutic Amvuttra (Vutrisiran) For Wild-type Or Hereditary Transthyretin Amyloidosis In Adult Patients With Cardiomyopathy As An Additional Indication

The U.S. Court of Appeals for the Federal Circuit (CAFC) on Wednesday affirmed a district court&#8217;s finding of noninfringement in favor of Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) in its ongoing patent battle with Alnylam Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) over mRNA-based <a href="https://www.benzinga.com/topic/covid-19">COVID-19 vaccine technology</a>, including its Spikevax COVID-19 vaccine.
The court held that Alnylam had acted as its lexicographer in defining the term &#8220;branched alkyl&#8221; in its patent specifications. That definition was included in Alnylam&#8217;s infringement allegations against Moderna&#8217;s Spikevax vaccine.
The <a target="_blank" href="https://www.cafc.uscourts.gov/opinions-orders/23-2357.OPINION.6-4-2025_2525006.pdf" rel="noreferrer noopener">case</a> centered on whether Alnylam&#8217;s patents, U.S. Patent Nos.&nbsp;11,246,933&nbsp;and&nbsp;11,382,979 were infringed by Moderna&#8217;s use of SM-102-a cationic lipid in Moderna&#8217;s COVID-19 vaccine formulations.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45624037/robert-f-kennedy-jr-says-cdc-drops-covid-vaccine-for-healthy-pregnant-women-kids" rel="noreferrer noopener">Robert F. Kennedy Jr. Says CDC Drops COVID Vaccine For &#8216;Healthy&#8217; Pregnant Women, Children</a>
Alnylam asserted that SM-102 fell within the scope of its claims, specifically limitations requiring a &#8220;branched alkyl&#8221; group in the hydrophobic tail of a cationic lipid. SM-102 enables intracellular delivery of mRNA in Moderna&#8217;s vaccine, making it central to Alnylam&#8217;s infringement theory.
In March 2022, Alnylam sued Moderna, alleging that Moderna infringed claim 18 and other claims of the '933 patent through activities involving the SM-102 lipid in its mRNA-based COVID-19 vaccine.
In July 2022, after the '979 patent was issued, Alnylam filed a similar suit against Moderna in the same forum, alleging infringement of claim 1 and other claims of the '979 patent. The two <a target="_blank" href="https://www.benzinga.com/general/biotech/22/07/28082091/alnylam-hits-moderna-with-another-patent-infringement-suit-related-to-covid-19-vaccine" rel="noreferrer noopener">actions were consolidated</a>.
In October 2024, Alnylam and&nbsp;Moderna reached a stipulation in their ongoing&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41169029/alnylams-concedes-its-patent-infringement-case-against-modernas-covid-19-vaccine" rel="noreferrer noopener">patent infringement litigation</a>.
Based on the court&#8217;s claim construction, Alnylam acknowledged it couldn&#8217;t secure a favorable judgment regarding the accused products&#8217; infringement of its patents.
The final stipulation allows for judgment in favor of Moderna, confirming that its currently formulated products do not infringe on Alnylam&#8217;s patents.
Both parties have agreed to dismiss the counterclaims and affirmative defenses raised by Moderna without prejudice, leaving the door open for further legal action if necessary in the future.
In October 2024, Northwestern University filed a patent infringement lawsuit against&nbsp;Moderna, alleging the pharmaceutical company used the university&#8217;s lipid nanoparticle (LNP) technology without permission to develop&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41381861/moderna-hit-with-another-lawsuit-related-to-key-covid-19-vaccine-technology" rel="noreferrer noopener">its COVID-19 vaccines.</a>
According to the&nbsp;<a target="_blank" href="https://fingfx.thomsonreuters.com/gfx/legaldocs/dwpkkdaxjpm/NORTHWESTERN%20MODERNA%20PATENT%20LAWSUIT%20complaint.pdf?tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" rel="noreferrer noopener">lawsuit</a>, the development of Moderna&#8217;s COVID-19 vaccine, Spikevax, depended on key technological advancements made at Northwestern.
Recently, The U.S. Food and Drug Administration (FDA) approved Moderna&#8217;s mNexspike&nbsp;(mRNA-1283), a new vaccine against COVID-19, for all adults 65 and older and individuals aged 12-64 years with at least one or more underlying risk factors as defined by the Centers for Disease&nbsp;<a target="_blank" href="https://www.benzinga.com/news/fda/25/06/45719840/modernas-new-covid-vaccine-secures-fda-clearance-for-seniors-at-risk-individuals" rel="noreferrer noopener">Control and Prevention (CDC)</a>.
Moderna shared Phase 3 immunogenicity data for its flu/COVID combination vaccine (mRNA-1083) for adults aged 50 and older at its 2024 R&amp;D Day event.&nbsp;
The company submitted mRNA-1083 for regulatory approval in older adults in 2024. Based on FDA feedback confirming the need for Phase 3 flu efficacy data, Moderna expects an extended review timeline and is now <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45145598/moderna-expands-cost-cutting-program-by-up-to-17-billion-fda-approval-for-flucovid-19-combo-shot-delayed-into-2026" rel="noreferrer noopener">targeting approval in 2026</a>.
Price Action: MRNA stock is down 1.32% at $26.91, and ALNY stock is up 0.69% at $307.43 at last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45790736/ciena-stock-slides-after-q2-eps-miss-margin-drop-despite-strong-sales" target="_blank" rel="noreferrer noopener">Ciena Stock Slides After Q2 EPS Miss, Margin Drop Despite Strong Sales</a></li>
</ul>
Photo by Wolfilser via Shutterstock

Legal

Moderna Beats Alnylam Appeal In COVID Vaccine Patent Case

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 20 years by 12.14% on an annualized basis producing an average annual return of 20.3%. Currently, Alnylam Pharmaceuticals has a market capitalization of $36.66 billion. 
Buying $1000 In ALNY: If an investor had bought $1000 of ALNY stock 20 years ago, it would be worth $38,973.12 today based on a price of $283.25 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748302212_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today

– Analysis Presented at the Heart Failure 2025 Congress Supports Primary Findings, Highlighting Impact of AMVUTTRA, which Delivers Rapid Knockdown of Transthyretin –
– Additional 42-Month Data Reinforce Vutrisiran's Impact on the Risk of All-Cause Mortality and Further Underscore the Effect on Cardiovascular Mortality –
– Vutrisiran Demonstrated Substantial Benefit Across a Range of Cardiovascular Events, Notably Reducing Urgent Heart Failure Visits by 46% in the Overall Patient Population During the Double-Blind Period –
– Findings Simultaneously Published in JACC –
– Details of TRITON-CM Phase 3 Study Evaluating Alnylam's Investigational Next-Generation TTR Silencer, Nucresiran, to be Presented at Congress –

Reported Saturday, Alnylam's Vutrisiran Reduces All-Cause And Cardiovascular Mortality By Over 30% In ATTR-CM Patients, New 42-Month HELIOS-B Data Show

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.alnylam.com%2F&amp;esheet=54252800&amp;newsitemid=20250512731729&amp;lan=en-US&amp;anchor=Alnylam+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=c09d64a6df2c8aec7de70fcaf5351a15">Alnylam Pharmaceuticals, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>), the leading RNAi therapeutics company, today announced that the Company will present the latest data from its flagship transthyretin amyloidosis (TTR) franchise at the upcoming Heart Failure 2025 Congress, a scientific congress of the European Society of Cardiology, taking place May 17-20 in Belgrade, Serbia.
The latest analyses of the HELIOS-B Phase 3 study of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM), including further outcomes data on cardiovascular hospitalizations and urgent heart failure visits up to 42-months, will be presented as a late-breaking abstract in the "Hottest Trials and Trial Updates 1" session.
Data from the HELIOS-B study supported the recent approvals of AMVUTTRA&#xAE; (vutrisiran) for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults in the U.S. and Brazil. These data also supported the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval of vutrisiran for the same indication. AMVUTTRA is an RNAi therapeutic that works upstream to deliver rapid knockdown of transthyretin, addressing the disease at its source, with four subcutaneous doses per year.
Additional updates to be presented include the design and rationale of the TRITON-CM Phase 3 study of nucresiran (ALN-TTRsc04), an investigational next-generation TTR silencer, in patients with ATTR-CM, as well as an additional analysis from the HELIOS-B study of vutrisiran in patients with ATTR-CM who experienced disease progression while being treated with tafamidis.

Alnylam Pharma To Present Latest Data From Flagship Transthyretin Amyloidosis Franchise At Upcoming Heart Failure 2025 Congress

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 15 years by 8.93% on an annualized basis producing an average annual return of 20.2%. Currently, Alnylam Pharmaceuticals has a market capitalization of $33.44 billion. 
Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 15 years ago, it would be worth $1,535.06 today based on a price of $258.35 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746743413_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today

UBS analyst Esther Rajavelu maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and raises the price target from $331 to $349.

UBS Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $349

Alnylam Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) on Thursday reported a first-quarter 2025 adjusted EPS loss of 1 cent, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus loss of $(1.03)</a>.
The company reported quarterly sales of $594.2 million, up 20% year over year, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45132168/alnylam-pharmaceuticals-reports-first-quarter-2025-financial-results-and-highlights-recent-period-" rel="noreferrer noopener">consensus of $585.8 million</a>.
<ul>
<li>Net product revenues increased 28% and 30% at actual currency and CER, respectively, due to growth from Amvuttra driven by increased patient demand, partially offset by a decrease in Onpattro due to patient switches to Amvuttra, and an increased number patients on Givlaari.</li>
<li><a href="https://www.benzinga.com/25/03/44463008/jp-morgan-sees-convincing-multi-billion-dollar-opportunity-for-alnylam-pharmaceuticals-upgrades-stock" target="_blank" rel="noreferrer noopener">Amvuttra</a> and Onpattro sales for the first quarter reached&nbsp;$310 million&nbsp;and&nbsp;$49 million, respectively, representing 36% growth compared to Q1 2024.</li>
<li>Givlaari and Oxlumo sales reached $67 million&nbsp;and&nbsp;$42 million, respectively, representing 8% growth.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44652995/vertex-alnylam-best-positioned-as-biopharma-braces-for-tariff-impact-goldman-sachs-analyst-flags-regeneron-biogen-risks" rel="noreferrer noopener">Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks</a>
Guidance: Alnylam affirmed fiscal 2025 sales guidance of $2.70 billion-$3 billion compared to the consensus of $2.91 billion, including:
<ul>
<li>Total TTR net product revenues (Amvuttra and Onpattro) of $1.6 billion-$1.725 billion.</li>
<li>Total rare net product revenues (Givlaari and Oxlumo) of $450 million&nbsp;&#8211;&nbsp;$525 million.</li>
</ul>
On Monday, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of Alnylam&#8217;s vutrisiran for wild type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). European Commission decision is <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b45036384/alnylam-receives-positive-chmp-opinion-for-vutrisiran-for-the-treatment-of-attr-amyloidosis-with-c" rel="noreferrer noopener">expected in June 2025</a>.
&#8220;Commercially, we believe that the totality of the data leaves Amvuttra well positioned to achieve significant market share as 1st line therapy, and we are encouraged by the launch activities discussed on the conference call,&#8221; Chardan analyst Keay Nakae writes.
Nakae maintains the Buy rating with a<a href="https://www.benzinga.com/quote/ALNY/analyst-ratings" target="_blank" rel="noreferrer noopener"> price target of $325</a>.
William Blair analyst Myles R. Minter writes, &#8220;On the ongoing Section 232 review of potential pharmaceutical tariffs, management highlighted minimal predicted exposure given that the majority of manufacturing processes and IP are housed within the U.S.&#8221;
Minter writes, &#8220;We continue to see Amvuttra as well positioned and differentiated in the lucrative TTR-CM market and would be buyers of Alnylam stock ahead of future quarters. Despite intraday volatility in trading, in part due to investor questions over why TTR-CM launch metrics like patient or script volume numbers were not provided when they are for BridgeBio Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>) Attruby, we believe management remains confident about Amvuttra&#8217;s potential and early access/reimbursement metrics provided appear favorable for a product in the infancy of a launch.&#8221;
Price Action: ALNY stock was up 1.67% at $259.39 on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/25/05/45169853/taiwan-semiconductor-gains-on-strong-earnings-from-meta-and-microsoft-boosting-ai-demand" target="_blank" rel="noreferrer noopener">Taiwan Semiconductor Gains On Strong Earnings From Meta And Microsoft Boosting AI Demand</a></li>
</ul>
Photo: Gorodenkoff/Shutterstock

Analyst Color

Earnings

Guidance

BBIO

Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Telsey Advisory Group cut Kohl&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) price target from $10 to $9. Telsey Advisory Group analyst Dana Telsey maintained a Market Perform rating. Kohl&#8217;s shares closed at $7.21 on Thursday. <a href="https://www.benzinga.com/quote/KSS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham raised the price target for Duolingo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) from $400 to $460. Needham analyst Ryan MacDonald maintained a Buy rating. Duolingo shares closed at $400.00 on Thursday. <a href="https://www.benzinga.com/quote/DUOL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Chardan Capital raised Alnylam Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) price target from $300 to $325. Chardan Capital analyst Keay Nakae maintained a Buy rating. Alnylam Pharmaceuticals shares closed at $255.13 on Thursday. <a href="https://www.benzinga.com/quote/ALNY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity slashed the price target for Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) from $100 to $80. Canaccord Genuity analyst Joseph Vafi maintained a Buy rating. Block shares closed at $58.48 on Thursday. <a href="https://www.benzinga.com/quote/XYZ/analyst-ratings">See how other analysts view this stock.</a></li>
<li>D. Boral Capital cut the price target for GeoVax Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) from $14 to $9. D. Boral Capital analyst Jason Kolbert maintained a Buy rating. GeoVax Labs shares closed at $0.9893 on Thursday. <a href="https://www.benzinga.com/quote/GOVX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>DA Davidson raised Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) price target from $230 to $250. DA Davidson analyst Gil Luria maintained a Buy rating. Apple shares settled at $213.32 on Thursday. <a href="https://www.benzinga.com/quote/AAPL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies cut Arvinas, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) price target from $52 to $10. Jefferies analyst Akash Tewari downgraded the stock from Buy to Hold. Arvinas shares closed at $7.23 on Thursday. <a href="https://www.benzinga.com/quote/ARVN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Telsey Advisory Group cut Clear Secure, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YOU#NYSE">YOU</a>) price target from $42 to $32. Telsey Advisory Group analyst Dana Telsey maintained an Outperform rating. Clear Secure shares closed at $24.40 on Thursday.  <a href="https://www.benzinga.com/quote/YOU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham lowered the price target for Five9, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) from $52 to $40. Needham analyst Scott Berg maintained a Buy rating. Five9 shares settled at $25.08 on Thursday. <a href="https://www.benzinga.com/quote/FIVN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity increased Strategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) price target from $409 to $464. Canaccord Genuity analyst Joseph Vafi maintained a Buy rating. Strategy shares closed at $381.60 on Thursday. <a href="https://www.benzinga.com/quote/MSTR/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying AAPL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="606" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02075526/image-23-1024x606.png" alt="" class="wp-image-898959" style="width:588px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02075526/image-23-1024x606.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02075526/image-23-300x177.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02075526/image-23-768x454.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02075526/image-23.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45133450/jim-cramer-this-consumer-cyclical-stock-is-a-one-trick-pony"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45133450/jim-cramer-this-consumer-cyclical-stock-is-a-one-trick-pony">Jim Cramer: This Consumer Cyclical Stock Is A &#8216;One-Trick Pony&#8217;</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

ARVN

FIVN

GOVX

MSTR

Apple To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Friday

Chardan Capital analyst Keay Nakae maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and raises the price target from $300 to $325.

Chardan Capital Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $325

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 20 years by 11.06% on an annualized basis producing an average annual return of 19.26%. Currently, Alnylam Pharmaceuticals has a market capitalization of $34.08 billion. 
Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 20 years ago, it would be worth $3,333.42 today based on a price of $263.34 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746112529_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today

Alnylam Pharmaceuticals Affirms FY2025 Sales Guidance of $2.70B-$3.00B vs $2.91B Est

Earnings Beats

Alnylam Pharmaceuticals Q1 Adj. EPS $(0.01) Beats $(1.03) Estimate, Sales $594.19M Beat $585.82M Estimate

AAMI

ABNB

ACCO

ADPT

AGCO

AGIO

ALHC

ALKS

ALSN

AMGN

AMWL

AMZN

APLE

APTV

ARDX

ASND

ASPS

ASUR

ATEC

ATEN

AXTI

BBAI

BIIB

BJRI

BLDR

BMRN

BOOM

BPMC

BRFH

CABO

CARR

CART

CERS

CMLS

COHN

COHU

COLM

COMM

COOK

CRAI

CTRE

CUBE

CWST

DBRG

DINO

DSGR

ECVT

ELME

Earnings Scheduled For May 1, 2025

Press Releases

Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress

Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference

Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress

AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B

Alnylam Issues 2024 Corporate Responsibility Report

Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference

Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Management

Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program

Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer

AbbVie

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

BioMarin Pharmaceutical

BioNTech

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Caris Life Sciences

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Incyte

Insmed

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeOne Medicines Ltd. - American Depositary Shares

BeOne Medicines

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

Needham

BMO Capital

JP Morgan

Chardan Capital

지난주에 가장 성과가 좋았던 대형주 10종목은 다음과 같다.
<ol>
<li>앨나일람 파마슈티컬스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>): 주가가 17.20% 상승했다. 이는 회사가 RNAi 치료제인 AMVUTTRA에 대한 sNDA를 FDA로부터 승인받았기 때문이다. 이 치료제는 성인 ATTR-CM 치료제이다.<a href="https://www.benzinga.com//node/44436749" target="_blank" rel="noreferrer noopener">자세한 내용은 여기에서 확인해 보자.</a></li>
<li>로쿠 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>): 주가가 15.51% 급등했다. 트럼프 미디어 앤 테크놀로지 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>)이 트루스 플러스(Truth+) <a href="https://www.benzinga.com//node/44405898" target="_blank" rel="noreferrer noopener">스트리밍 앱을 로쿠 플랫폼에 출시했다는 발표</a> 이후 상승했다.</li>
<li>로빈후드 마켓츠 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>): 주가가 13.05% 상승했다. 이는 컴퍼스 포인트가 주식을 매수 등급으로 커버리지를 시작하고 <a href="https://www.benzinga.com/quote/hood/analyst-ratings" target="_blank" rel="noreferrer noopener">목표주가를 61달러로 발표한 후</a> 나타났다.</li>
<li>엘빗 시스템즈 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLT#NASDAQ">ESLT</a>): 주가가 11.72% 상승했다. 이는 회사가 2024년 4분기 실적이 예상보다 좋았고 <a href="https://www.benzinga.com//node/44376371" target="_blank" rel="noreferrer noopener">분기 배당금을 주당 0.60달러로 인상</a>했다고 발표한 후 나타났다.</li>
<li>보잉 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>): 주가가 10.07% 상승했다. 트럼프 대통령이 보잉과 차세대 전투기 계약을 한다고 발표했기 때문이다.</li>
<li>앵글로골드 아샨티 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AU#NYSE">AU</a>): 주가가 10.05% 상승했다. 이는 금과 은의 가격 상승 때문으로 보이며, 금 가격이 사상 최고가를 기록했다.</li>
<li>쇼피파이 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>): 주가가 9.87% 상승했다. 이는 연방준비제도가 <a href="https://www.benzinga.com//node/44406912" target="_blank" rel="noreferrer noopener">금리 동결을 결정한 후</a> 전반적인 시장이 강세를 보인 결과로 볼 수 있다.</li>
<li>사우스웨스트항공 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>): 주가가 9.77% 상승했다. 여러 애널리스트들이 <a href="https://www.benzinga.com//node/44417227" target="_blank" rel="noreferrer noopener">가격 전망을 상향 조정했다.</a></li>
<li>미쓰비시 UFJ 파이낸셜 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUFG#NYSE">MUFG</a>):  주가가 9.66% 상승했다. 이는 연준의 금리 유지 결정 후 전반적인 시장 심리와 동조된 결과로 보인다.</li>
<li>듀오링고 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>): 주가가 9.09% 상승했다. 시티즌즈 캐피털 마켓츠가 주식 평가 등급을 시장수익률 상회로 상향 조정하고 목표주가를 400달러로 발표한 후 상승했다.</li>
</ol>
이미지 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Alnylam Pharmaceuticals

뉴스

에 대한 최신 뉴스 Alnylam Pharmaceuticals (NASDAQ:ALNY) 주식

일요일, 3월 23, 2025

일요일, 10월 06, 2024

일요일, 8월 04, 2024

일요일, 7월 07, 2024

화요일, 7월 02, 2024

일요일, 6월 30, 2024

화요일, 6월 25, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌